DF/HCC Program Affiliation

Translational Pharmacology and Early Therapeutic Trials
Kidney Cancer

Research Abstract

The focus of our research is on bringing new therapeutic agents and regimens into clinical use for patients with genitourinary malignancy. In prostate cancer, we are testing a novel marine-based drug, ET-743, and studying the use of other new chemotherapy regimens in patients with advanced disease. Together with Dr. Matthew Smith, we continue to have an interest in understanding bone metabolism in patients with and without skeletal metastases from prostate cancer, and in developing bone-targeted treatment approaches. Many of these efforts are done in collaboration with other members and resources of the Prostate SPORE grant supervised by Dr. Phil Kantoff.

In renal cell carcinoma, there is great interest in new biologic agents, particularly small molecule angiogenesis inhibitors such as SU11248, PTK787 and Bay 43-9006. Each of these is in clinical testing at our institution and offer great promise. Future studies will continue to examine newer agents and combination therapies. We have established collaborative efforts within the Renal SPORE grant to focus on translational kidney cancer research, including tumor and serum banking with identification of serum tumor markers for diagnostic and potentially therapeutic purposes. Our interest in bone metabolism extends to kidney cancer, with a current clinical trial focusing on the potential impact of anti-osteoclast therapy with bisphosphonates in this disease.

We have also established a program for transitional cell carcinoma research, and will have clinical trials opening soon in both localized and advanced bladder cancer. One such study will continue a long tradition at Massachusetts General Hospital of studying selective bladder preservation therapy for muscle-invasive bladder cancer, and will incorporate new biologic agents into this program. We anticipate that many of the efforts described will lead in the near future to advances in our care of patients with these advanced malignancies.

Publications

• Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR.Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.Cancer 2006 Jun 27.
  16804927
• Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.Sunitinib in patients with metastatic renal cell carcinoma.JAMA 2006 Jun 7;295(21):2516-24.
  16757724
• Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and
  16330672
• Michaelson MD, Smith MR.Bisphosphonates for treatment and prevention of bone metastases.J Clin Oncol 2005 Nov 10;23(32):8219-24.
  16278476
• Michaelson MD, Smith MR.The role of bisphosphonates in the management of metastatic prostate cancer.Curr Oncol Rep 2003 May;5(3):245-9.
  12667423
• Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW.A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.Cancer 2003 Jan 1;97(1):148-54.
  12491516